The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase.
U-31,355, or 4-amino-2-(benzylthio)-6-chloropyrimidine is an inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and possesses anti-HIV activity in HIV-1-infected lymphocytes grown in tissue culture. The compound acts as a specific inhibitor of the RNA-directed DNA polymerase function of HIV-1RT and does not impair the functions of the DNA-catalyzed DNA polymerase or the Rnase H of the enzyme. Kinetic studies were carried out to elucidate the mechanism of RT inhibition by U-31,355. The data were analyzed using Briggs-Haldane kinetics, assuming that the reaction is ordered in that the template:primer binds to the enzyme first, followed by the addition of dNTP, and that the polymerase is a processive enzyme. Based on these assumptions, a velocity equation was derived that allows the calculation of all the essential forward and backward rate constants for the reactions occurring between the enzyme, its substrates, and the inhibitor. The results obtained indicate that U-31,355 acts as a mixed inhibitor with respect to the template:primer and dNTP binding sites associated with the RNA-directed DNA polymerase domain of the enzyme. The inhibitor possessed a significantly higher binding affinity for the enzyme-substrate complexes, than for the free enzyme and consequently did not directly affect the functions of the substrate binding sites. Therefore, U-31,355 appears to impair an event occurring after the formation of the enzyme-substrate complexes, which involves either inhibition of the phosphoester bond formation or translocation of the enzyme relative to its template:primer following the formation of the ester bond. Moreover, the potency of U-31,355 depends on the base composition of the template:primer in that the inhibitor showed a much higher binding affinity for the enzyme-poly (rC):(dG)10 complexes than for the poly (rA):(dT)10 complexes.
Althaus
I W
IW
Upjohn Laboratories, Kalamazoo 49007-4940, MI USA.
Chou
K C
KC
Lemay
R J
RJ
Franks
K M
KM
Deibel
M R
MR
Kezdy
F J
FJ
Resnick
L
L
Busso
M E
ME
So
A G
AG
Downey
K M
KM
Romero
D L
DL
Thomas
R C
RC
Aristoff
P A
PA
Tarpley
W G
WG
Reusser
F
F
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015658:HIV Infections / Q000188:drug therapy / Q000201:enzymology; D054303:HIV Reverse Transcriptase; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000821:virology; D008432:Mathematical Computing; D051379:Mice; D011743:Pyrimidines / Q000494:pharmacology; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism; D012190:Retroviridae / Q000201:enzymology; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism*; D016914:Ribonuclease H / Q000037:antagonists & inhibitors / Q000378:metabolism; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism
C098910:4-amino-2-(benzylthio)-6-chloropyrimidine; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D014764:Viral Proteins; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D016914:Ribonuclease H